Mirati Therapeutics Inc. (NASDAQ: MRTX) has experienced a decline in its stock price by -12.08 compared to its previous closing price of 43.84. However, the company has seen a fall of -13.94% in its stock price over the last five trading days.
Is It Worth Investing in Mirati Therapeutics Inc. (NASDAQ: MRTX) Right Now?
The 36-month beta value for MRTX is also noteworthy at 1.01. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The average price estimated by analysts for MRTX is $66.80, which is $31.39 above than the current price. The public float for MRTX is 54.21M, and at present, short sellers hold a 12.47% of that float. The average trading volume of MRTX on May 25, 2023 was 995.63K shares.
MRTX’s Market Performance
The stock of Mirati Therapeutics Inc. (MRTX) has seen a -13.94% decrease in the past week, with a -10.55% drop in the past month, and a -14.52% fall in the past quarter. The volatility ratio for the week is 4.77%, and the volatility levels for the past 30 days are at 4.72% for MRTX. The simple moving average for the past 20 days is -16.41% for MRTX’s stock, with a -32.63% simple moving average for the past 200 days.
MRTX Trading at -9.11% from the 50-Day Moving Average
After a stumble in the market that brought MRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.95% of loss for the given period.
Volatility was left at 4.72%, however, over the last 30 days, the volatility rate increased by 4.77%, as shares sank -11.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.54% lower at present.
During the last 5 trading sessions, MRTX fell by -13.78%, which changed the moving average for the period of 200-days by -52.95% in comparison to the 20-day moving average, which settled at $45.86. In addition, Mirati Therapeutics Inc. saw -14.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRTX starting from Christensen Jamie, who sale 619 shares at the price of $45.29 back on May 24. After this action, Christensen Jamie now owns 124,123 shares of Mirati Therapeutics Inc., valued at $28,035 using the latest closing price.
Cherrington Julie M, the Director of Mirati Therapeutics Inc., sale 2,546 shares at $44.66 during a trade that took place back on Jan 18, which means that Cherrington Julie M is holding 0 shares at $113,704 based on the most recent closing price.
Stock Fundamentals for MRTX
Current profitability levels for the company are sitting at:
- -6107.98 for the present operating margin
- +71.62 for the gross margin
The net margin for Mirati Therapeutics Inc. stands at -5957.44. The total capital return value is set at -60.99, while invested capital returns managed to touch -59.67. Equity return is now at value -71.90, with -61.20 for asset returns.
Based on Mirati Therapeutics Inc. (MRTX), the company’s capital structure generated 5.17 points at debt to equity in total, while total debt to capital is 4.91. Total debt to assets is 4.28, with long-term debt to equity ratio resting at 4.38. Finally, the long-term debt to capital ratio is 4.17.
When we switch over and look at the enterprise to sales, we see a ratio of 86.10, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 3.98 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.96.
Conclusion
In summary, Mirati Therapeutics Inc. (MRTX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
